In this issue:
Pyroptosis burden is associated with anti-TNF outcome in IBD
Real-world ustekinumab persistence in IBD treatment
JAK inhibitors for IBD
Fibroblast heterogeneity and intercellular interactions in stricturing CD
Adding immunomodulators improves infliximab, but not vedolizumab or ustekinumab, pharmacokinetics
Preclinical serological signatures associated with complicated CD phenotype at diagnosis
Gut virome-colonising Orthohepadnavirus genus associated with UC pathogenesis
Thiopurine maintenance in paediatric UC
Declining hospitalisations in IBD patients
Potential missed CD diagnoses in tertiary care
Please login below to download this issue (PDF)